ALDR News and Press, Alder BioPharmaceuticals Inc. From 09/16/19

Gainers:  Alder BioPharmaceuticals (NASDAQ: ALDR ) +84% . SemGroup Corporation (NYSE: SEMG ) +63% . Yuma Energy (NYSEMKT: YUMA ) +63% . Wins Finance Holdings (NASDAQ: WINS ) +55% . Whiting Petroleum Corporation (NYSE: WLL ) +43% . New Concept Energy (NYSEMKT: GBR ) +34% . Califo...

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) to H. Lundbeck A/S (“Lundbeck”) is fair to Alder shareholders. On behalf of Alder sharehold...

Yuma Energy (NYSEMKT: YUMA ) +91%  as Oil and gas names up big after Saudi strike. More news on: Yuma Energy, Inc., Alder BioPharmaceuticals, Inc., SemGroup Corporation, Stocks on the move, , Energy stocks news Read more ...

H. Lundbeck A/S ( OTC:HLUKF ) has agreed to acquire Alder BioPharmaceuticals (NASDAQ: ALDR ) for $18 per share in cash plus one non-tradeable Contingent Value Right (CVR) for an additional $2 per share if migraine med eptinezumab is approved by the European Medicines Agency (EMA). The total ...

- Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine - - Preclinical data also to be presented for ALD1910, Alder’s second candidate for migraine, demonstrating its bind...

Satsuma Pharmaceuticals ( STSA ) has a product candidate at Phase 3 of development and is targeting a large market. With other competitors trading with a valuation of $0.6-1.5 billion, after the IPO, we expect the company to sell around these marks. Market participants will need to carefully r...

REDWOOD CITY, Calif. , Sept. 4, 2019 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, today announced that it has appointed Randall Schatzman , Ph.D. to the position of chief executive office...

BOTHELL, Wash., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview...

For the past couple years, Alder BioPharmaceuticals Inc. ( ALDR ) has been fighting a losing battle as an also-ran in a field dominated by giants of biopharma. The company has a drug called Eptinezumab targeting episodic as well as chronic migraines. Eptinezumab is a Calcitonin gene-related pe...

Quick Take Satsuma Pharmaceuticals ( STSA ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the development of a treatment of acute migraine headache. STSA has begun Phase 3 trials and expects to pu...